Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

61.31 USD UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Sep 17, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,284
Open 61.31
Bid (Size) 60.75 (2)
Ask (Size) 60.84 (3)
Prev. Close 61.31
Today's Range 61.31 - 61.31
52wk Range 56.75 - 69.75
Shares Outstanding 2,222,113,553
Dividend Yield 3.20%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients w
U.S. FDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination... 
From Business Wire News Releases
Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal Junction or Esophageal Adenoc
BMS Receives Positive CHMP Opinion for Opdivo + Chemotherapy for Patients with HER2-Negative Advanced or Metastatic Gastric, Gastroesophageal.... 
From Business Wire News Releases

Performance

YTD
-0.11%
-0.11%
1 Month
-11.40%
-11.40%
3 Month
-8.26%
-8.26%
6 Month
-3.27%
-3.27%
1 Year
+6.13%
+6.13%

More News

Read More
Five-Year Data from CheckMate -214 Show Opdivo (nivolumab) Plus Yervoy (ipilimumab) Demonstrates Longest Median Overall Survival Currently Reported in Phase 3 Trial of Patients with Previously Untreat
From Business Wire News Releases
Gritstone Unveils "Off-The-Shelf" Neoantigen Immunotherapy Data In Lung Cancer
Tags GRTS Non/Small Cell Lung Cancer Phase 1 Trial
From Benzinga
Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer
Tags ESMO21 Briefs Market News
From Benzinga
These Industries Stand To Benefit From The Infrastructure Bill — And These Companies Are Lobbying Against It
Tags Politics General Benzinga
From Benzinga
With Prothena Up Over 500% This Year, Is It Too Late to Get in?
Tags PRTA BIIB BMY
From Motley Fool
Bristol Myers Touts 5-Year Kidney Cancer Data For Opdivo-Yervoy Combo Therapy
Tags Biotech Benzinga General
From Benzinga
Visualizing the World’s Biggest Pharmaceutical Companies
Tags Healthcare Pharma/Biotech Stocks / Equities
From TalkMarkets
Noteworthy Thursday Option Activity: ULTA, BMY, NKE
Tags Stocks
From Market News Video
8 Health Care Stocks With Unusual Options Alerts In Today's Session
Tags BMY PFE MRNA
From Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.